CRC Research Update — November 15, 2026
Today's colorectal cancer research highlights
Curated CRC research, accessible, accurate, actionable
The CRC Digest
Sunday, November 15, 2026
IMPORTANT: The CRC Digest curates and summarizes publicly available research for informational and educational purposes only. Nothing in this newsletter constitutes medical advice, diagnosis, or treatment recommendation. The information provided should not be used as a substitute for professional medical advice. Always seek the guidance of your physician or other qualified health provider with any questions regarding a medical condition or treatment. Content is generated with AI assistance and reviewed by the editorial team. We are not medical professionals. Individual results, treatments, and outcomes vary.
CRC Research Update
-
TRIAL DATA
Antibiotic plus immunotherapy combination shows activity in F. nucleatum-positive MSS metastatic CRCA multicenter phase 2 trial of 33 patients with Fusobacterium nucleatum-positive, microsatellite-stable metastatic CRC treated with tislelizumab, fruquintinib, and metronidazole achieved a median progression-free survival of 6.0 months, with an objective response rate of 19.4% and disease control rate of 83.9%. (Cancer Cell)
-
SCREENING
Bacterial signature test after positive FIT reduces colonoscopies but misses some cancersAmong 1,291 participants with positive FIT in a Galician screening program, the RAID-CRC Screen bacterial test would have avoided 15.8% of colonoscopies while missing two CRCs and 55 advanced neoplasms; raising the FIT threshold alone avoided fewer colonoscopies but retained all observed cancers. (Diagnostics)
-
RESEARCH
IgA antibody suppresses colon cell proliferation and tumor formation in micePreclinical experiments in mice found that IgA deficiency increased susceptibility to colorectal cancer models; oral IgA treatment reduced epithelial proliferation and protected against tumors through interaction with the surface protein DMBT1. (Nature)
-
SCREENING
Blood biomarker hPG80 shows promise for CRC screening and treatment monitoringA scoping review of five studies encompassing 2,692 participants found that plasma hPG80 was significantly overexpressed in CRC patients compared to controls and decreased significantly after surgery, though optimal thresholds and stage-specific correlations remain to be established. (Biomarker Insights)
This week's research spans early detection strategies, microbiome-targeted therapies, and geographic disparities in young-onset disease.
Get CRC research intelligence delivered weekly, free.
SubscribeCRC Digest
Not Medical Advice
The CRC Digest provides research summaries for informational and educational purposes only. This is not medical advice. Always consult your healthcare provider before making any decisions about your care.
Content is curated with AI assistance and reviewed by the editorial team.
Browse Past Issues · Read our full disclaimer · Manage subscription
Useful? Forward it to a colleague. Many of the topics named here have a live research dossier, trajectory and evidence, at Signal Bureau.
Got this from a colleague? Subscribe here. Readers are added at their own request, by sign-up or through Evolution Labs.
Evolution Accelerator, Inc. (dba Evolution Labs) · 3941 Park Dr., Suite 20341, El Dorado Hills, CA 95762
You are receiving this because you subscribed to CRC Digest (self-serve signup)
Unsubscribe: honored promptly, no login required. · Privacy policy · Manage or delete your data